Future Biogas & AstraZeneca 15-year partnership – represents the “blueprint” transaction in biomethane markets and wished model for biomethane producers and developers.

For more info&facts about the transaction please see Bioenergy Insight Nov/Dec 2023 article.

The most striking for me is the determination of AstraZeneca´s management to finalise this transaction which negotiations started in covid period and its decision-making ability to pay significant premium above market price of unsubsidised biomethane supply as well as for gas molecules, thus motivating Future Biogas to build new biomethane capacities. Local use of biomethane underlines the pure long-term GPA nature of this biomethane supply.

Who is to be next industry major to follow this biomethane market development beneficial pattern?

In my view, most multinational corporations prefer to use their pricing power to their advantage, purchase biomethane certificates that are being traded with discount to physical biomethane to fulfill their sustainability obligations with no interest in buying locally sourced biomethane from local producers, the pattern we see more and more in renewable power market.

And when we see first similar biomethane producer – industrial end user GPA in Eastern Europe?